InsidersTradesSigma
Follow the DANAHER CORP share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, DANAHER CORP has logged 71 insider filings. Market capitalisation: €142.3bn. The latest transaction was filed on 6 February 2026 (Attribution). Among the most active insiders: Weidemanis Joakim. All data is accessible without an account.
71
Insider Decl.
n/a
Thresholds
€23,747
1 ops.
Buy Volume
€14m
11 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate DANAHER CORP Strong Buy (bullish), based on 23 analysts. Average price target: US$242.52.
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 14,696 of 29,062 companies
51.7
score / 100
Value42
Quality62
FCF yld3.7%
Earn yld2.5%
EV/EBITDA23.5x
ROE7.6%
Gross mgn59%
Net mgn15%
Debt/EBITDA2.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 February 2026
Declarations71 total
1,695 shares0Common StockSEC:0000313616-26-000055:0
1,413 shares0Common StockSEC:0000313616-26-000053:0
1,046 shares0Common StockSEC:0000313616-26-000056:0
848 shares0Common StockSEC:0000313616-26-000052:0
679 shares0Common StockSEC:0000313616-26-000049:0
1,695 shares0Common StockSEC:0000313616-26-000054:0
8,474 shares0Common StockSEC:0000313616-26-000051:0
2,684 shares0Common StockSEC:0000313616-26-000050:0
372 shares0Common StockSEC:0000313616-22-000145:0
372 shares0Common StockSEC:0000313616-22-000151:0
170 shares@ US$249.190.0000% mcap15.8% of flowCommon StockSEC:0000313616-22-000142:0
372 shares0Common StockSEC:0000313616-22-000149:0
372 shares0Common StockSEC:0000313616-22-000144:0
372 shares0Common StockSEC:0000313616-22-000147:0
100 shares@ US$247.890.0000% mcap0.4% of flowCommon Stock, par value $.01SEC:0000899243-22-018400:0
Canonical exit: 14 Aug 2022 (T+90)
372 shares0Common StockSEC:0000313616-22-000141:0
372 shares0Common StockSEC:0000313616-22-000148:0
372 shares0Common StockSEC:0000313616-22-000150:0
372 shares0Common StockSEC:0000313616-22-000146:0
6,500 shares@ US$255.7350.0014% mcap11.4% of flowCommon StockSEC:0000313616-22-000113:0
921 shares0Common StockSEC:0000313616-22-000093:0
260 shares@ US$271.560.0001% mcap100.0% of flowCommon StockSEC:0000313616-22-000095:0
22,770 shares0Common StockSEC:0000313616-22-000078:0
652 shares@ US$271.560.0001% mcap61.0% of flowCommon StockSEC:0000313616-22-000076:0
25 of 71 declarations
关于 DANAHER CORP
Danaher Corp /DE/（股票代码：DHR）是一家在美国纽约证券交易所上市的主要美国公司。它已从一家多元化的工业收购商发展成为一个专注于生命科学、诊断和生物技术的科学技术平台。该公司总部位于华盛顿特区，业务遍及全球50个国家和大约700个地点，反映了其广泛的国际足迹，支持制造、研发、销售和服务活动。Danaher成立于1984年，通过严谨的收购、卓越的运营和Danaher商业系统建立了声誉，该系统仍然是该集团整合和改进所收购业务的核心部分。（[danaher.com](https://www.danaher.com/global-locations?utm_source=openai)） Danaher目前报告了三个主要的运营平台：生物技术、诊断和生命科学。生物技术包括Cytiva和Pall等领先品牌，提供支持生物加工、治疗开发和制造的技术、耗材和服务。诊断提供旨在提高诊断信心和速度的临床检测和患者护理解决方案，而生命科学涵盖用于研究、药物开发和生物分析的科学仪器、试剂、软件和工作流程解决方案。这种结构使Danaher能够涉足医疗保健价值链的多个环节，从基础研究到大规模生物制造和临床诊断。（[danaher.com](https://danaher.com/our-businesses?utm_source=openai)） 从竞争角度来看，Danaher以其强大的市场地位、知名品牌、经常性耗材收入、已安装基础优势以及在复杂、受监管的终端市场中的执行声誉而闻名。该公司还强调其生物技术特许经营的规模，指出其生物技术业务支持全球很大一部分已批准的单克隆抗体生产，突显了其在生物制药供应链中的重要性。（[danaher.com](https://www.danaher.com/about-danaher?utm_source=openai)） 近期发展表明了运营势头和产品组合扩张。2026年1月，Danaher公布了2025年全年业绩，包括24.6 billion美元的收入和3.0%的同比增长。2026年2月，该公司宣布了一项收购Masimo的协议，此举旨在加强其专业诊断能力。对于投资者而言，DHR仍然是一家高质量的医疗保健和工具复合型公司，在生物加工、诊断和生命科学领域具有结构性长期增长敞口，并得到长期资本配置框架和全球业务范围的支持。（[investors.danaher.com](https://investors.danaher.com/2026-01-28-Danaher-Reports-Fourth-Quarter-and-Full-Year-2025-Results?utm_source=openai)）
